|
CBL completes validation of an additional GMP oven, increasing available capacity to its current level.
The expansion of the GMP production and storage areas is completed to its present size.
Completed the manufacturing of approximately 150 million doses of small pox vaccine for the National Strategic Stockpile.
High-speed vial filling line qualification is completed in Building C, significantly expanding capacity and lot size capabilities.
Building B manufacturing facility completed in order to manufacture smallpox vaccine.
Pre-filled syringe manufacturing capacity is expanded.
A new Hull 240ft2 lyophilizer is installed in Building C, expanding lyophilization capacity.
In January 2001, Cangene Corporation of Winnipeg, Manitoba, Canada purchased CBL.
All manufacturing and operations were successfully transferred to the Camden Industrial Park facility. Seton facility closed.
The initial FDA inspection of the completed 70,000 ft2 GMP production facility at Camden Industrial Park Facility, 1111 S. Paca St., Baltimore, MD.
In February of 1997, corporate headquarters, warehouse facilities and shipping and receiving operations were relocated to their current location, the Camden Industrial Park facility.
CBL expanded its facility to include sterile fill/finish of experimental biopharmaceuticals by offering GMP manufacturing services to the emerging biotech industry.
CBL relocated its corporate headquarters to a 15,000ft2 facility in the Seton Industrial Park. The Company expanded its administrative, research and laboratory and manufacturing facilities.
CBL founded in 1980. In conjunction with the Johns Hopkins University of Medicine, CBL began to provide biochemical analysis of synovial fluid samples from racing horses to assist veterinarians in the diagnosis and management of joint disorders. With synovial samples arriving from all over the world, the Company gained an international reputation.
|
1987